- Published
- 10 October 2024
- Journal article
Emergence of the B.1.214.2 SARS-CoV-2 lineage with an Omicron-like spike insertion and a unique upper airway immune signature
- Authors
-
- Source
- BMC Infectious Diseases
Abstract
We investigate the emergence, mutation profile, and dissemination of SARS-CoV-2 lineage B.1.214.2, first identified in Belgium in January 2021. This variant, featuring a 3-amino acid insertion in the spike protein similar to the Omicron variant, was speculated to enhance transmissibility or immune evasion. Initially detected in international travelers, it substantially transmitted in Central Africa, Belgium, Switzerland, and France, peaking in April 2021. Our travel-aware phylogeographic analysis, incorporating travel history, estimated the origin to the Republic of the Congo, with primary European entry through France and Belgium, and multiple smaller introductions during the epidemic. We correlate its spread with human travel patterns and air passenger data. Further, upon reviewing national reports of SARS-CoV-2 outbreaks in Belgian nursing homes, we found this strain caused moderately severe outcomes (8.7% case fatality ratio). A distinct nasopharyngeal immune response was observed in elderly patients, characterized by 80% unique signatures, higher B- and T-cell activation, increased type I IFN signaling, and reduced NK, Th17, and complement system activation, compared to similar outbreaks. This unique immune response may explain the variant's epidemiological behavior and underscores the need for nasal vaccine strategies against emerging variants.
Rights
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Cite as
Holtz, A., Van Weyenbergh, J., Hong, S., Cuypers, L., O’Toole, Á., Dudas, G., Gerdol, M., Potter, B., Ntoumi, F., Mapanguy, C., Vanmechelen, B., Wawina-Bokalanga, T., Van Holm, B., Menezes, S., Soubotko, K., Van Pottelbergh, G., Wollants, E., Vermeersch, P., Jacob, A., Maes, B., Obbels, D., Matheeussen, V., Martens, G., Gras, J., Verhasselt, B., Laffut, W., Vael, C., Goegebuer, T., van der Kant, R., Rousseau, F., Schymkowitz, J., Serrano, L., Delgado, J., Wenseleers, T., Bours, V., André, E., Suchard, M., Rambaut, A., Dellicour, S., Maes, P., Durkin, K. & Baele, G. 2024, 'Emergence of the B.1.214.2 SARS-CoV-2 lineage with an Omicron-like spike insertion and a unique upper airway immune signature', BMC Infectious Diseases, 24, article no: 1139. https://doi.org/10.1186/s12879-024-09967-w